In an exclusive interaction with NDTV, Managing Director of Novo Nordisk India, Vikrant Shrotriya, said the launch of ...

Novo Nordisk has approached the Delhi High Court to prevent Dr Reddy’s Laboratories from manufacturing and exporting ...

Looking to expand its footprint in the booming glucagon-like peptide (GLP-1) market, Danish drugmaker Novo Nordisk has ...

Novo Nordisk has launched Ozempic in India at ₹2,200 per week, expanding diabetes treatment options even as patent disputes ...

Earlier, the court had declined Novo’s plea for an interim injunction against Dr Reddy’s Labs and permitted the company to ...

Ozempic, which is injected once a week under careful medical supervision, is said to help control diabetes and help Type 2 ...

We recently published 13 Best ADR Stocks to Invest In. Novo Nordisk A/S (NYSE:NVO) is one of the best ADR stocks. Healthcare giant Novo Nordisk A/S (NYSE:NVO)’s shares were downgraded by Argus ...

Novo Nordisk says it is taking a flexible portfolio approach and plans to price the injectable semaglutide close to Wegovy’s ...

EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in ...

In early December 2025, Novo Nordisk reported phase 3 Evoke and Evoke+ trial results showing oral semaglutide did not improve ...

The launch comes amid the company’s legal battle with Indian drugmakers, including Dr Reddy’s Laboratories and Sun Pharma, ...

With this launch, Ozempic now available in India as a once-weekly injectable formulation of semaglutide. It will be available ...